High-level JAG1 mRNA and protein predict poor outcome in breast cancer - PubMed (original) (raw)
High-level JAG1 mRNA and protein predict poor outcome in breast cancer
Brendan C Dickson et al. Mod Pathol. 2007 Jun.
Free article
Abstract
Notch receptors regulate cell fate determination, stem cell self-renewal, proliferation and apoptosis. We previously reported that elevated mRNA expression of the Notch ligand JAG1 identifies breast cancer patients with a poor prognosis. Here we show through immunohistochemical analysis of the same breast cancer cases (N=127) that patients with tumors expressing high levels of JAG1 protein had a worse outcome than those with tumors expressing low levels (10-year survival 26 vs 48%, and median survival 63 vs 108 months, respectively; P=0.03). We also describe the novel application of the Allred score to quantify JAG1 mRNA and protein expression levels. Using the Allred score, patients with tumors expressing high levels of JAG1 mRNA had a worse outcome than those with tumors expressing low levels (10-year survival 16 vs 47%, and median survival 43 months vs 100 months, respectively; P<0.001). Interestingly, when tumors were classified as either high or low for JAG1 mRNA or protein expression, there was only 65% agreement (kappa=0.08) between the two methods of expression analysis. When JAG1 mRNA and protein data were combined, patients with tumors expressing low levels of both had a 10-year survival of 53% and median survival of 131 months. In comparison, patients with tumors expressing either high levels of JAG1 protein, mRNA or both had reduced 10-year survival and median survival (31%, 19%, 11% and 77, 43, 23 months respectively; P<0.0001). There was marginal evidence of an interaction effect (P=0.055), which indicated that the prognostic value of JAG1 protein was limited to the JAG1 mRNA-low subgroup. These data show that the Allred score can be used to rapidly quantify JAG1 mRNA and protein levels in breast cancer to identify patients who have a significant survival disadvantage and who may benefit from therapies (such as gamma-secretase inhibitors) that target signaling through the Notch pathway.
Similar articles
- High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival.
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. Reedijk M, et al. Cancer Res. 2005 Sep 15;65(18):8530-7. doi: 10.1158/0008-5472.CAN-05-1069. Cancer Res. 2005. PMID: 16166334 - JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.
Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL. Reedijk M, et al. Breast Cancer Res Treat. 2008 Oct;111(3):439-48. doi: 10.1007/s10549-007-9805-3. Epub 2007 Nov 8. Breast Cancer Res Treat. 2008. PMID: 17990101 - Spatial localization of the JAG1/Notch1/osteopontin cascade modulates extrahepatic metastasis in hepatocellular carcinoma.
Xue TC, Zou JH, Chen RX, Cui JF, Tang ZY, Ye SL. Xue TC, et al. Int J Oncol. 2014 Nov;45(5):1883-90. doi: 10.3892/ijo.2014.2630. Epub 2014 Aug 29. Int J Oncol. 2014. PMID: 25176314 - Jagged1 (JAG1): Structure, expression, and disease associations.
Grochowski CM, Loomes KM, Spinner NB. Grochowski CM, et al. Gene. 2016 Jan 15;576(1 Pt 3):381-4. doi: 10.1016/j.gene.2015.10.065. Epub 2015 Nov 6. Gene. 2016. PMID: 26548814 Free PMC article. Review. - Anti-Jagged-1 immunotherapy in cancer.
Pancewicz J, Niklinska W, Eljaszewicz A. Pancewicz J, et al. Adv Med Sci. 2022 Sep;67(2):196-202. doi: 10.1016/j.advms.2022.04.001. Epub 2022 Apr 11. Adv Med Sci. 2022. PMID: 35421813 Review.
Cited by
- Notch2 activation by benzyl isothiocyanate impedes its inhibitory effect on breast cancer cell migration.
Kim SH, Sehrawat A, Singh SV. Kim SH, et al. Breast Cancer Res Treat. 2012 Aug;134(3):1067-79. doi: 10.1007/s10549-012-2043-3. Epub 2012 Apr 4. Breast Cancer Res Treat. 2012. PMID: 22476855 Free PMC article. - The Notch signaling pathway as a mediator of tumor survival.
Capaccione KM, Pine SR. Capaccione KM, et al. Carcinogenesis. 2013 Jul;34(7):1420-30. doi: 10.1093/carcin/bgt127. Epub 2013 Apr 12. Carcinogenesis. 2013. PMID: 23585460 Free PMC article. Review. - High BMI Is Associated with Changes in Peritumor Breast Adipose Tissue That Increase the Invasive Activity of Triple-Negative Breast Cancer Cells.
Miracle CE, McCallister CL, Denning KL, Russell R, Allen J, Lawrence L, Legenza M, Krutzler-Berry D, Salisbury TB. Miracle CE, et al. Int J Mol Sci. 2024 Oct 1;25(19):10592. doi: 10.3390/ijms251910592. Int J Mol Sci. 2024. PMID: 39408921 Free PMC article. - Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.
Rasul S, Balasubramanian R, Filipović A, Slade MJ, Yagüe E, Coombes RC. Rasul S, et al. Br J Cancer. 2009 Jun 16;100(12):1879-88. doi: 10.1038/sj.bjc.6605034. Br J Cancer. 2009. PMID: 19513078 Free PMC article. - Dll4-Notch signaling as a therapeutic target in tumor angiogenesis.
Kuhnert F, Kirshner JR, Thurston G. Kuhnert F, et al. Vasc Cell. 2011 Sep 18;3(1):20. doi: 10.1186/2045-824X-3-20. Vasc Cell. 2011. PMID: 21923938 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical